Beta-Thalassemia Withdrawn Phase 2 Trials for Deferasirox (DB01609)

Also known as: Beta-thalassemia / Thalassemia beta / Beta thalassemia / Beta thalassaemia / Beta thalassemia major / Thalassaemia beta / Beta-thalassaemia

IndicationStatusPhase
DBCOND0027982 (Beta-Thalassemia)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01927913Treatment of Iron Overload Requiring Chelation TherapyTreatment